Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Cited In for PubMed (Select 18273714)

1.

Applying the ARRIVE Guidelines to an In Vivo Database.

Karp NA, Meehan TF, Morgan H, Mason JC, Blake A, Kurbatova N, Smedley D, Jacobsen J, Mott RF, Iyer V, Matthews P, Melvin DG, Wells S, Flenniken AM, Masuya H, Wakana S, White JK, Lloyd KC, Reynolds CL, Paylor R, West DB, Svenson KL, Chesler EJ, de Angelis MH, Tocchini-Valentini GP, Sorg T, Herault Y, Parkinson H, Mallon AM, Brown SD.

PLoS Biol. 2015 May 20;13(5):e1002151. doi: 10.1371/journal.pbio.1002151. eCollection 2015 May.

2.

BJP is changing its requirements for scientific papers to increase transparency.

McGrath JC, Curtis MJ.

Br J Pharmacol. 2015 Jun;172(11):2671-4. doi: 10.1111/bph.12954.

PMID:
25966314
3.

Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis.

Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM.

J Neuroinflammation. 2015 May 13;12:90. doi: 10.1186/s12974-015-0310-z.

4.

Expectations for methodology and translation of animal research: a survey of health care workers.

Joffe AR, Bara M, Anton N, Nobis N.

BMC Med Ethics. 2015 May 7;16:29. doi: 10.1186/s12910-015-0024-x.

5.

The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development.

Heslop E, Csimma C, Straub V, McCall J, Nagaraju K, Wagner KR, Caizergues D, Korinthenberg R, Flanigan KM, Kaufmann P, McNeil E, Mendell J, Hesterlee S, Wells DJ, Bushby K.

Orphanet J Rare Dis. 2015 Apr 23;10:49. doi: 10.1186/s13023-015-0258-1.

6.

A brief review of recent Charcot-Marie-Tooth research and priorities.

Ekins S, Litterman NK, Arnold RJ, Burgess RW, Freundlich JS, Gray SJ, Higgins JJ, Langley B, Willis DE, Notterpek L, Pleasure D, Sereda MW, Moore A.

F1000Res. 2015 Feb 26;4:53. doi: 10.12688/f1000research.6160.1. eCollection 2015. Review.

7.

Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis.

Tokuda E, Watanabe S, Okawa E, Ono S.

Neurotherapeutics. 2015 Apr;12(2):461-76. doi: 10.1007/s13311-015-0346-x.

PMID:
25761970
8.

SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice.

Dirren E, Aebischer J, Rochat C, Towne C, Schneider BL, Aebischer P.

Ann Clin Transl Neurol. 2015 Feb;2(2):167-84. doi: 10.1002/acn3.162. Epub 2015 Jan 15.

9.

Advice on statistical analysis, and new journal guidance for experimental design and analysis.

Curtis MJ, Abernethy DR.

Pharmacol Res Perspect. 2015 Feb;3(1):e00095.

10.

Activity-dependent degeneration of axotomized neuromuscular synapses in Wld S mice.

Brown R, Hynes-Allen A, Swan AJ, Dissanayake KN, Gillingwater TH, Ribchester RR.

Neuroscience. 2015 Apr 2;290:300-20. doi: 10.1016/j.neuroscience.2015.01.018. Epub 2015 Jan 21.

11.

The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia.

Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG.

PLoS One. 2015 Jan 21;10(1):e0116919. doi: 10.1371/journal.pone.0116919. eCollection 2015.

12.

Stem cell therapy in spinal trauma: Does it have scientific validity?

Chhabra HS, Sarda K.

Indian J Orthop. 2015 Jan-Feb;49(1):56-71. doi: 10.4103/0019-5413.143913.

13.

How clinical trials of myasthenia gravis can inform pre-clinical drug development.

Rostedt Punga A, Kaminski HJ, Richman DP, Benatar M.

Exp Neurol. 2015 Aug;270:78-81. doi: 10.1016/j.expneurol.2014.12.022. Epub 2015 Jan 13.

PMID:
25592627
14.

Inhibiting drug efflux transporters improves efficacy of ALS therapeutics.

Jablonski MR, Markandaiah SS, Jacob D, Meng NJ, Li K, Gennaro V, Lepore AC, Trotti D, Pasinelli P.

Ann Clin Transl Neurol. 2014 Dec;1(12):996-1005. doi: 10.1002/acn3.141. Epub 2014 Nov 21.

15.

Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Hooten KG, Beers DR, Zhao W, Appel SH.

Neurotherapeutics. 2015 Apr;12(2):364-75. doi: 10.1007/s13311-014-0329-3.

PMID:
25567201
16.

Dexpramipexole is ineffective in two models of ALS related neurodegeneration.

Vieira FG, LaDow E, Moreno A, Kidd JD, Levine B, Thompson K, Gill A, Finkbeiner S, Perrin S.

PLoS One. 2014 Dec 19;9(12):e91608. doi: 10.1371/journal.pone.0091608. eCollection 2014.

17.

Improving the predictive value of interventional animal models data.

Zeiss CJ.

Drug Discov Today. 2015 Apr;20(4):475-82. doi: 10.1016/j.drudis.2014.10.015. Epub 2014 Nov 4. Review.

PMID:
25448761
18.

PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.

Joardar A, Menzl J, Podolsky TC, Manzo E, Estes PS, Ashford S, Zarnescu DC.

Hum Mol Genet. 2015 Mar 15;24(6):1741-54. doi: 10.1093/hmg/ddu587. Epub 2014 Nov 28.

PMID:
25432537
19.

Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits.

Heier CR, Guerron AD, Korotcov A, Lin S, Gordish-Dressman H, Fricke S, Sze RW, Hoffman EP, Wang P, Nagaraju K.

PLoS One. 2014 Nov 12;9(11):e112477. doi: 10.1371/journal.pone.0112477. eCollection 2014.

20.

New forms of checks and balances are needed to improve research integrity.

Iorns E, Chong C.

F1000Res. 2014 May 28;3:119. doi: 10.12688/f1000research.3714.1. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk